JPM vs OPY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
OPY presents a complex profile where deep value metrics conflict with deteriorating forward-looking indicators. The company maintains a stable health profile with a Piotroski F-Score of 6/9 and trades significantly below both its Graham Number ($165.9) and Intrinsic Value ($384.68). However, a critical divergence exists between the trailing P/E (8.78) and the Forward P/E (44.72), suggesting a projected collapse in earnings. Combined with a very bearish technical trend (10/100) and insider selling, the current price reflects a market that is pricing in a significant earnings contraction despite historical growth.
Compare Another Pair
Related Comparisons
JPM vs OPY: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Oppenheimer Holdings Inc. (OPY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.